Sarcoidosis: many faces, one disease. Narrative review of the literature

Andrés Chavarriaga-Restrepo¹, Juan Esteban López-Amaya², Miguel Antonio Mesa-Navas³, Carlos Jaime Velásquez-Franco⁴

¹ Internist, CES Clinic, Medellin, Colombia.
² Radiologist, Bolivarian University Clinic, Medellin, Colombia.
³ Teacher, School of Health Sciences, Universidad Pontificia Bolivariana (Pontifical Bolivarian University), Medellin, Colombia.
⁴ Professor of Internal Medicine, School of Health Sciences. Universidad Pontificia Bolivariana (Pontifical Bolivarian University), Rheumatology Section. Bolivarian University Clinic. Medellin Colombia.

Correspondence: Andrés Chavarriaga-Restrepo; andresch_1@hotmail.com

Received: March 31, 2018
Accepted: August 31, 2018

References: Chavarriaga-Restrepo A, López-Amaya JE, Mesa-Navas MA, Velásquez-

SUMMARY

Sarcoidosis is a systemic granulomatous disease of unknown etiology. It affects patients of all types and ages, being more frequent between the third and fourth decade of life with a second peak around fifth decade in the Scandinavian and Japanese populations. It is more common in women and severe in the Afro-descendant population. Antigens that initiate this granulomatous response are unknown, however, they are presumed to be airborne as a result of the lung involvement high frequency in this disease. Its clinical manifestation covers a wide range of manifestations, including acute and limited forms to chronic with progressive organ damage and death. Its diagnosis is based on the existence of non-caseating granulomas in tissues, excluding other diseases such as mycobacterial infection.

KEYWORDS

Lymphadenopathy; Lung; Sarcoidosis

RESUMEN

Sarcoidosis: muchas caras, una enfermedad. Revisión narrativa de la literatura

La sarcoidosis es una enfermedad granulomatosa sistémica de etiología desconocida. Esta puede afectar a pacientes de todas las latitudes y edades, siendo más frecuente entre la tercera y cuarta década de la vida con un segundo pico alrededor de los 50 años en las poblaciones
escandinava y japonesa. Es más frecuente en mujeres y grave en la población afrodescendiente. Los antígenos que inician esta respuesta granulomatosa son desconocidos, pero se presume que son aerotransportados por la alta frecuencia de compromiso pulmonar en esta enfermedad. Su presentación clínica abarca una amplia gama de manifestaciones, desde formas agudas y limitadas hasta el compromiso crónico con daño orgánico progresivo y muerte. Su diagnóstico se basa en la existencia de los granulomas no caseificantes en los tejidos, con la exclusión de otras enfermedades, entre ellas infección por micobacterias.

PALABRAS CLAVE
Linfadenopatía; Pulmón; Sarcoidosis

INTRODUCTION

Sarcoidosis is a systemic granulomatous disease of unknown etiology and global distribution (1). Its diagnosis is based on the exclusion of other diseases which can cause granulomas with non-caseating necrosis, added to the involvement of at least two organs in patient with compatible symptoms (2).

Its origin dates back to 1899, when Boeck gave the name to multiple benign sarcoid injuries in the extensor regions of the upper limbs of a 36-year-old policeman. The presence of epithelioid cells with a large and pale nucleus was found in the microscopic analysis, associated with some giant cells which had a sarcoma appearance, which is the reason why this name was given at that time and it is preserved until today (3).

In recent years there has been a breakthrough in knowledge about the physiopathology, clinical manifestations and treatment of the disease; and we will address some of them
during the following review.

**EPIDEMIOLOGY**

From the epidemiological standpoint, the sarcoidosis disease can affect patients of all types and ages, it is more frequent between the third and fourth decade of life, with a second peak around fifth decade in the Scandinavian and Japanese populations (4, 5). It is 1.5 times more common in women (5), with a reported prevalence of 1-60 out of 100,000 patients that varies according to the location and race of the different reported series, as it is higher in whites and afro-descendants, and three times more frequent in the second one as shown in Table 1 (6).

<table>
<thead>
<tr>
<th>Population / Race</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S</td>
<td>10-40/100.000</td>
</tr>
<tr>
<td>African Americans</td>
<td>35,4-60/100.000</td>
</tr>
<tr>
<td>whites</td>
<td>10,4-14/100.000</td>
</tr>
<tr>
<td>Scandinavian</td>
<td>50-60/100.000</td>
</tr>
<tr>
<td>Japan</td>
<td>1-2/100.000</td>
</tr>
<tr>
<td>Argentina Brazil</td>
<td>1,5/100.000</td>
</tr>
</tbody>
</table>

Source: reference 18.

It is also important to highlight that there is a variation not just in the prevalence of the disease but in its manifestation form according to the race, being more common the chronic forms and the ocular involvement in the afrodescendant population and the asymptomatic forms in the white population; thus impacting the prognosis of the disease, since the African-American population has a higher demand for steroids and less successful in clearing these. Another described variation is observed in Japan, where there is a higher incidence of a cardiac involvement described in autopsy studies, which is present in up to 50% of patients and is the leading cause of death (4, 5, 7).
In the local epidemiology there are a series of cases of the northeastern of Colombia (8) where 8 patients were included, 50% men with an average age of 40, the most frequent symptoms of the series is dyspnea 75%, followed by cough and weight loss. Lung involvement was observed in 50% of patients, being typically bilateral and upper lobe involvement (8). The Muñoz et al series was also found in Medellin with 22 patients, of whom 89% were women with an average age of 46, with cutaneous and joint symptoms, being the main cause of consultation, with an average symptoms time of 5 months at diagnosis. Fourteen patients had lung symptoms, 14 had skin symptoms determined by erythema nodosum, papules, changes in tattoos and Sweet syndrome and joint symptoms were reported (9) in 62% of patients.

**PHYSIOPATHOLOGY**

Although the physiopathology of sarcoidosis is not completely clear, it has been considered that its etiology can be triggered by an environmental agent, an antigen that in a susceptible host triggers this granulomatous reaction. Regarding the initial antigen, its identity is unknown, but it is presumed to be airborne, since some type of lung involvement occurs in 95% of the cases (10).

Several studies have been carried out in which genetic material has been found in granulomas, mainly mycobacteria (11), in order to identify this antigen. The above is supported by a study carried out at Johns Hopkins in which 9 patients with sarcoidosis and 14 controls without the disease were compared, in which 55% of the evaluated samples were found to have monoclonal antibodies anti-catalase peroxidase of M. tuberculosis in the sarcoidosis group and in none of the control group (12).
In the study of cases and controls to determine the etiology of sarcoidosis (ACCESS) (13), which recruited 736 patients, other triggering factors associated with certain occupations (poultry breeding, car manufacturing, gardening) and environmental exposures were found (insecticides, birds, cotton, radiation, organic dust, construction material), which reinforces the concept that a variety of antigens can trigger the disease in a patient with genetic susceptibility. Finally, the low socioeconomic status has also been associated with the development of this disease, partly explained by the poor access to health services and partly by the tendency to perform jobs with greater exposure to triggers in this group of people (14, 15).

As a disease, it has a systemic inflammatory component which is presumed to be due to the antigenic occurrence through the major histocompatibility complex with activation of Th1 lymphocytes. These infiltrate the lung and produce cytokines such as alpha Tumor Necrosis Factor (TNF-), the beta Transforming Growth Factor (TGF-) and interleukins 2 and 12, among others; which leads to the formation of granulomas with non-caseating necrosis and local microarchitecture damage (16).

Granulomas are composed of T CD4 lymphocytes (Th1) with activated macrophages, which simulate an epithelioid cell (called epithelioid granulomas), surrounded in turn by fibroblasts, B cells and T CD8 lymphocytes (4).

These epithelioid granulomas are the main source of Angiotensin-Converting Enzyme, described even as a diagnostic aid in the disease.

Granuloma formation is one of the disease's central axes and consists of 4 stages: initiation where macrophages and monocytes are recruited, the first internalize the antigen which they process and present, through the major histocompatibility complex type II to the T CD4
lymphocytes. Subsequently, the accumulation phase where there is an oligoclonal proliferation with a CD4 lymphocyte differentiation and an increase in the number of lymphocytes CD-4, CD-8 and monocytes occurs; followed by an effect phase involving several mediators such as interleukins 2 and 12 and the interferon gamma (IFN-γ). Finally, the future of the granuloma is defined based on the cytokines profile present at that time, in such a way that if antigenic clearance and IL-10 predominates, the route is changed to a Th2 type response with a subsequent limitation of the disease, and if the beta Transforming Growth Factor and cathelicidin 18 predominate, the fibrotic process that eventually will account the damage in the architecture and the dysfunction of the affected organs will be perpetuated (Image 1) (17, 18).
CLINICAL MANIFESTATION

As a systemic disease, it can affect any organ with a variable spectrum of manifestations from the asymptomatic forms, going through the self-limited forms of inherently benign course to the chronic forms with accumulated organ damage and a worse prognosis (16). Regarding the asymptomatic forms, they are usually diagnosed incidentally during the performance of a thoracic image, where typical findings of the disease are found given by symmetrical hilar adenopathies; which in 5% of the cases are unilateral or absent adenopathies, (6).

The acute forms are represented prototypically by Löfgren's syndrome, caused by the triad bilateral hilar lymphadenopathy, erythema nodosum and bilateral ankle arthritis. This, together with uveoparotid fever (Heerfordt's syndrome), constitute the two symptomatic scenarios in which it is possible to make the sarcoidosis diagnosis without histological confirmation (19).

The Löfgren syndrome has a similar distribution between men and women, a peak incidence between 30 and 40 years and a second peak in women between 45 and 65 years. Usually, It does not require treatment as it solves itself, which speaks of its good prognosis, being this an unusual form of manifestation in the African-American population (16). Heerfordt syndrome is also a manifestation of good prognosis and consists of the bilateral uveitis and parotitis presence, which is present in 73% of cases. The other typical symptoms completing this syndrome and that are less frequent are fever and facial paralysis (20).

The chronic forms have a worse prognosis and are more frequent in the black race, the mainly affected organ is the lung (90-95%), which can present a wide range of symptoms ranging from cough, dyspnea, occasional wheezing, hemoptysis and chest pain, and even the
involvement of the lung parenchyma with fibrosis (2, 21). This condition is what determines the disease prognosis in the non-Japanese population, due to the poor survival associated with advanced forms (22). Other involved systems in order of frequency are shown in Table 2. Regarding the multi-systemic involvement of the disease, the ACCESS study (13) found that 50% of patients had an organ involvement, 30% two organs and 20% in three or more organs.

<table>
<thead>
<tr>
<th>Organ Involvement</th>
<th>ACCESS (13)</th>
<th>MUSC (23)</th>
<th>TTS (24)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>736</td>
<td>1,582</td>
<td>293</td>
</tr>
<tr>
<td>Lung %</td>
<td>95</td>
<td>89</td>
<td>99</td>
</tr>
<tr>
<td>Skin %</td>
<td>16</td>
<td>32</td>
<td>16</td>
</tr>
<tr>
<td>Eye %</td>
<td>12</td>
<td>23</td>
<td>5</td>
</tr>
<tr>
<td>Peripheral lymphadenopathies %</td>
<td>15</td>
<td>12</td>
<td>13</td>
</tr>
<tr>
<td>Liver %</td>
<td>12</td>
<td>20</td>
<td>-</td>
</tr>
<tr>
<td>Spleen %</td>
<td>7</td>
<td>7</td>
<td>-</td>
</tr>
<tr>
<td>Neurological %</td>
<td>5</td>
<td>9</td>
<td>3</td>
</tr>
</tbody>
</table>

Source: adapted from reference 22

RADIOLOGICAL FINDINGS

More than 40 years ago, Siltzbach developed a sarcoidosis classification system based on a radiological findings pattern that is still widely used and has prognostic value. This classification defines 5 sarcoidosis stages summarized in Table 3. Each stage is related to a spontaneous remission probability that is 60-90% in patients with stage 1 disease, 40-70% with stage 2 disease (Image 2), 10-20% in patients with stage 3 disease and 0% in patients with stage 4 (23, 24).

<table>
<thead>
<tr>
<th>Sarcoidosis Stages based on Radiological Findings</th>
<th>ACCESS (13)</th>
<th>MUSC (23)</th>
<th>TTS (24)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>736</td>
<td>1,582</td>
<td>293</td>
</tr>
<tr>
<td>Lung %</td>
<td>95</td>
<td>89</td>
<td>99</td>
</tr>
<tr>
<td>Skin %</td>
<td>16</td>
<td>32</td>
<td>16</td>
</tr>
<tr>
<td>Eye %</td>
<td>12</td>
<td>23</td>
<td>5</td>
</tr>
<tr>
<td>Peripheral lymphadenopathies %</td>
<td>15</td>
<td>12</td>
<td>13</td>
</tr>
<tr>
<td>Liver %</td>
<td>12</td>
<td>20</td>
<td>-</td>
</tr>
<tr>
<td>Spleen %</td>
<td>7</td>
<td>7</td>
<td>-</td>
</tr>
<tr>
<td>Neurological %</td>
<td>5</td>
<td>9</td>
<td>3</td>
</tr>
</tbody>
</table>

Source: adapted from reference 22
Stage | Findings | Frequency of occurrence
--- | --- | ---
Stage 0 | Normal | 5 - 10 %
Stage 1 | Lymphadenopathies | 50 %
Stage 2 | Lymphadenopathies and lung infiltrates | 25 - 30 %
Stage 3 | Lung infiltrates | 10 - 12 %
Stage 4 | Fibrosis | 5 %

Sarcoidosis Classification based on Radiographic findings. Percentages indicate the proportion of patients diagnosed with sarcoidosis and their respective stage at the time of occurrence of the disease.

Image 2. 2A. High Resolution Computed Tomography in soft tissue window showing right paratracheal adenopathy. 2B. Shows bilateral and symmetrical hilar adenopathies (straight arrows) and conglomerate of subcarinal adenopathies (arrowhead).

This classification system was developed before the introduction of Computed Tomography (CT), and the collected information to date with regard to the prognosis is based on the radiography findings, not on CT. High resolution CT is more sensitive than radiography in the occurrence of subtle abnormalities of lung parenchyma in an early stage of the disease, even in stage 1 (21, 25); however, the prognosis value for tomographic findings has not yet been widely studied (26).

FINDINGS IN HIGH-RESOLUTION COMPUTED TOMOGRAPHY

High resolution CT is superior in contrast to the conventional CT in the evaluation and differentiation between inflammation and fibrosis in patients with lung sarcoidosis (27, 28).
Its better spatial resolution improves detection of reticular and nodular shadowing, thickening of interlobular septa and ground-glass opacity or shadowing. High resolution CT also has greater use in the differentiation between active inflammation and irreversible fibrosis in patients with stage 2 or 3 disease. Nodules, ground-glass opacity or shadowing and alveolar shadowing suggest a granulomatous inflammation which can be reversible with therapy (29). In contrast, honeycomb cysts, thick septal bands, distortion of the architecture, loss of volume and traction bronchiectasis indicate an irreversible fibrosis. High resolution tomography can also be useful to check diagnosis in patients with atypical clinical manifestations or with unusual radiological findings (30).

The most common sarcoidosis occurrence corresponds to the presence of right paratracheal and hilar bilateral symmetric adenopathies. Bilateral hilar adenopathies, alone or in combination with mediastinal adenopathies, occur in approximately 95% of patients with sarcoidosis (25, 31); left, subcarinal, aortopulmonary and prevascular paratracheal adenopathies are present in up to 50% of patients (28). Calcifications of the adenopathies are directly related to the duration of the granulomatous disease. They are seen in 3% of patients after 5 years and in 20%, after 10 years; they may have several appearances: amorphous, dotted, in the form of popcorn or egg shell.

Regarding the involvement of the lung parenchyma, the characteristic feature is the perilymphatic distribution of micronodular injuries (75-90% of cases), with a predominantly symmetrical bilateral distribution, although not invariably in the middle and upper areas. These nodules are usually found in the peribronchovascular interstitium, subpleural and interlobular septa, and can coalesce over time to form larger injuries (macronodules) (Image 3. Sarcoides granulomas also frequently cause nodular or irregular thickening of the peribronchovascular interstitium (29, 30).
Ground-glass Opacity or shadowing occurs in approximately 40% of patients and originates from the confluence of multiple micronodular granulomatous interstitial and fibrotic injuries, which generates compression but not the filling of the air space seen in the alveolitis (25, 27). The mosaic attenuation pattern in patients with sarcoidosis is the result of the involvement of the small airway by granulomas or fibrosis, which may cause an obstruction and be associated to air trapping, the latter is better visualized in the expiratory phases (32, 33).

Finally, fibrotic changes develop by up to 20% of patients can be seen, among which is the presence of thick septal bands, distortion of the architecture, loss of volume, cysts in the honeycomb and traction bronchiectasis, indicative findings of irreversible fibrosis (34). They are more common in the middle and upper lung fields, with a patchy distribution. In advanced cases they can be associated with lung hypertension and / or right heart failure.

Other less frequent radiological manifestations will not be addressed in this review.
OTHER CLINICAL MANIFESTATIONS

Ocular involvement due to sarcoidosis is described as the third most frequent in some series among 10-60% of patients (35). It produces an inflammation not only ocular but also in the annexes, occurring more commonly in Afro-descendant women.

Uveitis is the most named involvement, occurs in a heterogeneous manner and is more prevalent in the Japanese population, where it is reported in up to 15% of patients. Its occurrence has two peaks, the first of them in the third decade (usually associated with acute forms) and the second in the sixth or seventh (associated with chronic forms). Its symptoms may include lacrimation, photophobia, and conjunctival pain and injection. However, about one-third of patients with uveitis caused by sarcoidosis have no ocular symptoms (35, 36). It tends to be bilateral and has a preference for the anterior segment in 70 to 85% of the time with panuveitis in 9-30% of cases, the latter being a serious involvement that leads to blindness in 10% of patients, usually within the course of the first year after its debut (35, 37). The second most common involvement is conjunctiva, generally observed as nodules (37). Other less common forms are retinal vasculitis, Heerfordt's syndrome (previously described) and ocular proptosis also called Exophthalmos (38,39), taking into account that any ocular segment can be affected by this disease.

Cutaneous sarcoidosis occurs as the first symptom in 20-35% of patients, and can be a limited form to this organ in 70% of cases. There are specific skin occurrences that require the presence of non-caseating granulomas in the biopsy, and other called non-specific granulomas which do not meet this condition. The most frequent form reported in the literature is erythema nodosum, which is part of nonspecific injuries, in addition to calcifications, acropachy, pyoderma gangrenosum and Sweet syndrome (40). Specific skin
injuries are present in 9-15% of patients with sarcoidosis, represented by papules and plaques, lupus pernio (violaceous plaques), which should not be confused with cutaneous lupus. This injury usually occurs in the nose and cheeks, and represents a poor prognosis as it predicts a progression increased risk to chronic forms of the disease and lung manifestations. Other forms include sarcoidosis in scars, tattoos and subcutaneous nodules or Darier Roussy sarcoidosis (subcutaneous inflammation due to nodules) among others (40).

Joint manifestation due to sarcoidosis can simulate acute or chronic arthropathies, occurs in 25% of patients during the course of the disease. In the series by Muñoz et al., a high presence of arthritis in 62% of the ankles and joints in 59% of the cases was found (9), different than that reported in other Colombian series where half were men and the joint involvement was much lower, close to 8% (40); this difference is mainly explained by reference biases of the aforementioned studies (41). Bilateral arthritis of the ankle is characteristic of this disease, which has a sensitivity of 95% and a specificity of 90% in suspected cases of sarcoidosis (42, 43).

The sarcoidosis prevalence of the nervous system is reported between 3.5-7%, and cranial neuropathy is the most common (47-64%), followed by the central nervous system which is between 14-64% of patients and peripheral manifestations 3-14% (43).

In those patients with systemic disease and neurological symptoms, 60% coincide with the onset, 34% precede it and 6% occur after the onset of symptoms (44).

Renal sarcoidosis is rare and is usually asymptomatic (90% of cases) (45), with the remaining 10% being symptomatic and interstitial nephritis as the most associated (45). Clinically evident cardiac sarcoidosis has been described in 2-7% of patients, with hidden involvement reported in more than 20% of cases; It is important to note that sudden death
may be the initial manifestation (due to rhythm or conduction disorders), which may occur at any time during the illness. It is more typical in the Japanese population with incidences of 50 to 78% in necropsy studies, in which the main cause of death is heart failure (77-85%), unlike other races (13-50%) (7). Difficulties that arise with this form of manifestation are given by the definitive diagnosis, since the Endomyocardial Biopsy has a low performance and the diagnosis is based on non-invasive imaging studies; for which purpose, treatment in the absence of histological diagnosis is authorized (7).

The hepatic sarcoidosis is underestimated, 11.5% have been described according to the ACCESS study (10), since most of the patients are asymptomatic or their symptoms are not very specific, especially if histological involvement and Hepatic alterations tests are compared in the absence of symptoms. The biopsy is positive in 75% of the patients; and symptoms are usually abdominal pain, pruritus, fever, jaundice and weight loss. Hepatomegaly occurs in 5-15% of patients and the most described biochemical abnormality is the increased of alkaline phosphatase, present in 90% of symptomatic patients (46).

Hematological findings in patients with sarcoidosis are rare, peripheral lymphadenopathies, anemia, thrombocytopenia, chronic disease anemia, lymphopenia and leukopenia have been described, and these findings appear to be due to granulomas in the bone marrow or splenic sequestration (47).

**DIAGNOSIS**

As a disease, its diagnosis is challenging, since it is eminently discarded (48). For this, three conditions are required: the presence of granulomas non-caseating necrosis (ideally, in at least two organs) (18), discarding diseases with a similar phenotype and a compatible clinical picture (48). At the time of initiating the diagnosis process, the first step is to define whether
there is a multi-systemic involvement, then we must rule out the presence of any of the conditions in which the diagnosis of sarcoidosis can be made without the need of biopsy (as in Löfgren and Heerfordt syndrome) or in the presence of: asymptomatic bilateral hilar adenopathy and in the presence of panda sign and lambda signs on gallium-67 tracing (18). Subsequently, histological confirmation will be sought, giving priority to suspicious injuries easily accessible and, if not possible, the biopsy of mediastinal or hilar adenopathies will be defined. Finally, if there aren’t susceptible injuries, it may be useful to perform a blind biopsy in certain tissues as a conjunctiva with 55% positivity (49), salivary gland (20-58%) (50, 51), scalene lymph node (74 -80%) (52) and liver (50-60%) (53).

Historically, the increased levels of Angiotensin-Converting Enzyme (ACE) have been described in the diagnosis of the disease (54). The origin of this association is not entirely clear and seems to be related to the greater increased risk that some genotypes of the ACE confer to the disease.

Its sensitivity and specificity have been calculated in 41.4% and 89.9%, respectively, with a false positive rate of around 10%, so its use is not advisable, as a single test in the diagnosis of this disease (15, 54). Although these limitations are important in patients in whom the differential diagnosis is focused on other granulomatous diseases, the increase twice over the upper limit is highly specific for sarcoidosis and its highest clinical utility could reside there (55). Other aspects that may affect their performance are the family hyperactivity of the ACE, which is associated with high levels above three times the usual reference value in healthy people (56) and steroid treatment that can decrease such values. On the other hand, the usefulness in measuring ACE levels serially to determine the activity of the disease has not been demonstrated yet (55, 57). Other tests which can provide important information include tuberculin, which in patients with active sarcoidosis is generally negative by
Peripheral energy, being necessary to clarify that when having a positive tuberculin; tuberculosis should be searched as a cause of symptoms (58).

Some tests that have been discontinued in use include the Kveim Siltzbachm test, in which the tissue preferably from the spleen of a patient with sarcoidosis was used and applied subcutaneously. Subsequently, a biopsy was taken from the site of injury, four to six weeks later, and the formation of granulomas was observed. Although this test had a high sensitivity (87%) for the sarcoidosis diagnosis, the difficulties in obtaining the raw material due to its poor availability have left it aside to be a historical curiosity (59). Another study that has been performed routinely is marked scintigraphy with gallium-67, this test gives a characteristic uptake in the parotid and lacrimal glands "panda sign" and in the mediastinal region with paratracheal and pretracheal involvement "lambda sign".

The presence of these alterations is highly specific for sarcoidosis, however, due to its low sensitivity and poor availability, it is not a test commonly used in the clinical practice (60).

Finally, there are some innovations in the diagnostic models field to try to standardize this process in a disease like this without pathognomonic findings. For this reason the World Association of Sarcoidosis and other Granulomatous Diseases (World Association of Sarcoidosis and other Granulomatous Disorders, WASOG) developed a checklist of organ involvement by sarcoidosis, classifying them as highly probable, probable, possible and undefined (61). This instrument provides a better evaluation, although it doesn’t provide a score that allows to make a decision and which provides a known sensitivity and specificity.

Based on this checklist, a diagnostic sarcoidosis score has recently been developed that takes into account the clinical and the histological areas, in addition to providing cutting points with a known sensitivity. Thus, a score of 6 or more in the biopsy area results in a sensitivity of 99.3% and a specificity of 100%; and a score of 3 in the clinical area has a sensitivity of
94.2% and a specificity of 88.8%, which changes to 76.9% and 98.6%, respectively, if the cutting point is modified to 4. Although these findings have not yet been validated by other groups, they could allow a much friendlier approach (62).

**DIFFERENTIAL DIAGNOSIS**

Among the differential diagnoses it is always necessary to take into account the infectious causes, especially tuberculosis, since this disease is common in our environment (prevalence of 24.1 / 100,000 for 2013) and produces granulomatous injuries.

Other infections to be considered include some fungal infections such as histoplasma, which can also generate granulomas (63). Differential diagnosis usually requires a multidimensional approach where the histological finding must be evaluated by staining and culture to rule out infectious causes (64). The vasculitis associated with antibodies against the neutrophil cytoplasm (ANCA - Antineutrophil cytoplasmic antibodies), especially granulomatosis with polyangiitis, are a mandatory differential, since it induces non-caseating necrosis, lung, ocular and other organs involvement, where the presence of vasculitis in the biopsy will be one of the ways to differentiate it. There are other details in the evolution such as renal involvement, typical of this type of vasculitis, and the positivity of ANCA, especially by ELISA, which are particularly useful to perform this differentiation (14).

Common variable immunodeficiency is another diagnosis to consider, since granulomatous lung disease with lymphocytic infiltration associated with common variable immunodeficiency can be incorrectly diagnosed as sarcoidosis. It is a systemic disease, with lymphadenopathy, splenomegaly, extra and intra-pulmonary granulomatosis, with non-caseating necrosis. In this case, hypogammaglobulinemia and the flat gamma region in
protein electrophoresis guide the diagnosis. Finally, lung findings differ significantly despite similarities in biopsy, therefore, presence of the superior way and adenopathies in sarcoidosis are more frequent (65).

The Sjögren syndrome is part of the differential diagnosis of patients with sarcoidosis, because the parotidomegaly (also called Parotid enlargement) and the involvement of salivary glands and lacrimal glands are part of the described manifestations of the disease. There is autoimmunity of the exocrine glands in this syndrome, thus producing symptoms such as dry mouth and dry eyes. The coexistence of both diseases has been described, as in the case series of Ramos-Casals (66), in which it is detailed that both diseases share clinical, immunogenetic and pathogeny, what helps to differentiate the presence of antibodies in the Sjögren, usually negative in sarcoidosis, in addition to the salivary gland biopsy where predominance of CD8+ in sarcoidosis and, CD4+ in Sjögren make the difference, even before the doubts in the typical histological findings that may overlap (66).

In recent times, the disease has been described by IgG4 as multisystemic, characterized by the fibroinflammatory involvement of multiple organs: retroperitoneum, salivary glands, pancreas, ganglia, brain, skin, large vessels, among others. Manifested as pancreatitis, sclerosing cholangitis, interstitial nephritis, prostatitis, pneumonia and increased salivary glands (67). The aforementioned characteristics makes difficult to differentiate these two diseases, sometimes IgG4 is mistakenly treated, under the supposed diagnosis of sarcoidosis (68) and there are even reports in the literature of IgG4 pancreatitis with granulomatous involvement in mediastinal ganglia and lung, where coexistence of both is considered (69). Given this difficult situation, scintigraphy with gallium-67 has been proposed as a useful tool in differential diagnosis, through pancreas uptake, submandibular glands (especially if asymmetrical) in IgG4 disease, while in sarcoidosis it predominates in lacrimal glands,
supraclavicular, mediastinal adenopathies and muscle tissue (70).

Although this is not the purpose of this review, treatment varies from clinical observation in asymptomatic forms to a complete immunosuppressive treatment with alkylating agents in the most severe forms. Additionally, anti-TNF has been used as an alternative in refractory cases, which is logical due to the lytic effect of these on granulomas (71).

In conclusion, sarcoidosis is a multisystemic granulomatous disease difficult to identify. Its differential diagnosis is broad and requires a methodical discard process as there is no definitive diagnostic test. Finally, the treatment depends on the organ involvement degree and its chronicity.

CONFLICT OF INTEREST

None to be declared.

BIBLIOGRAPHIC REFERENCES


33. Davies CW, Tasker AD, Padley SP, Davies RJ, Gleeson FV. Air trapping in


43. Banse C, Goëb V. Do not forget the joint involvement of sarcoidosis.


Bickett AN, Lower EE, Baughman RP. Sarcoidosis Diagnostic Score: A Systematic


71. Baughman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: